Rucaparib or Physician's Choice in Metastatic Prostate Cancer

Current Oncology, Free Full-Text

Rucaparib extends PFS in advanced prostate cancer

Advances in the treatment of metastatic prostate cancer: Trends in Cancer

Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial - The Lancet Oncology

Role of rucaparib in the treatment of prostate cancer

Prostate cancer: The hunt for a silver bullet - Medical Independent

Prostate cancer and PARP inhibitors: progress and challenges, Journal of Hematology & Oncology

𝐂𝐡𝐚𝐧𝐝𝐥𝐞𝐫 𝐏𝐚𝐫𝐤 𝐌𝐃 𝐅𝐀𝐂𝐏 on X: ⚡️ Just RELEASED NEJM: Ph 3 trial Rucaparib mCRPC patients w/BRCA1, BRCA2, ATM after 2nd gen ARPI. ✓62 mo rPFS 11.2 mo vs 6.4 mo(Ruc vs

PDF] Trial of rucaparib in prostate indications 3 (TRITON3): An international, multicenter, randomized, open-label phase 3 study of rucaparib vs physician's choice of therapy for patients (Pts) with metastatic castration-resistant prostate cancer (

Advanced Prostate Cancer: Treatment Advances and Future Directions: Trends in Cancer

FDA Approves Olaparib, Rucaparib to Treat Prostate Cancer - NCI